title: A placebo-controlled trial of bupropion SR as an antidote for selective serotonin reuptake inhibitor-induced sexual dysfunction.
abstract: OBJECTIVE
  This study reports the results of a placebo-controlled, double-blind comparison of bupropion sustained release (SR) as an antidote for sexual dysfunction versus placebo in 42 patients with selective serotonin reuptake inhibitor (SSRI)-induced sexual dysfunction. Exploratory analyses of the association of testosterone and sexual functioning in women in the study were also performed.
  
  
  METHODS
  Patients with DSM-IV major depression who experienced a therapeutic response to any SSRI and were experiencing medication-induced global or phase-specific sexual dysfunction, as measured by the Changes in Sexual Functioning Questionnaire (CSFQ), were randomly assigned to receive either bupropion SR 150 mg b.i.d. or placebo for 4 weeks in addition to the SSRI. Total testosterone levels were assessed at baseline and week 4.
  
  
  RESULTS
  The difference in global sexual functioning, based on the total CSFQ score, was not statistically significant between the 2 groups at week 4, nor were differences in orgasm, desire/ interest as measured by sexual thoughts, or self-reported arousal. There was a statistically significant difference between the 2 groups at week 4 in desire as measured by self-report feelings of desire and frequency of sexual activity. Desire/ frequency showed a significantly greater improvement among those patients receiving bupropion SR compared with placebo (Wilk's F = 5.47, df = 1, p =.024). Frequency was significantly correlated to total testosterone level at baseline (r = 0.36, p =.027) and at week 4 (r = 0.41, p =.025).
  
  
  CONCLUSIONS
  Bupropion SR, as an effective antidote to SSRI-induced sexual dysfunction, produced an increase in desire to engage in sexual activity and frequency of engaging in sexual activity compared with placebo. A larger study is needed to further investigate this finding.
authors.affiliation: University of Virginia, Charlottesville, VA 22903, USA. ahc8v@virginia.edu
authors.forename: Anita H
authors.initials: AH
authors.lastname: Clayton
authors.forename: Julia K
authors.initials: JK
authors.lastname: Warnock
authors.forename: Susan G
authors.initials: SG
authors.lastname: Kornstein
authors.forename: Relana
authors.initials: R
authors.lastname: Pinkerton
authors.forename: Adrienne
authors.initials: A
authors.lastname: Sheldon-Keller
authors.forename: Elizabeth L
authors.initials: EL
authors.lastname: McGarvey
mesh_terms: D000284:Administration, Oral; D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000008:administration & dosage* / Q000494:pharmacology*; D001143:Arousal; D016642:Bupropion / Q000008:administration & dosage* / Q000494:pharmacology*; D003692:Delayed-Action Preparations; D003866:Depressive Disorder / Q000188:drug therapy*; D039721:Diagnostic and Statistical Manual of Mental Disorders; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010919:Placebos; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D012735:Sexual Dysfunction, Physiological / Q000139:chemically induced*; D013739:Testosterone / Q000097:blood
chemical_list: D018687:Antidepressive Agents, Second-Generation; D016642:Bupropion; D003692:Delayed-Action Preparations; D010919:Placebos; D017367:Selective Serotonin Reuptake Inhibitors; D013739:Testosterone